ELCC 2020 - The European Lung Cancer Congress
Apr 15 - Apr 18, 2020 | GenevaSwitzerland
LARVOL is not affiliated with The European Lung Cancer Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 17 abstracts linked to Trials
First-Line Tyrosine Kinase Inhibitor With or Without Aggressive Upfront Local Radiation Therapy In Patients With EGFRm Oligometastatic Non-Small-Cell Lung Cancer: Interim Results of A RandomizedPhase III, Open-Label ClinicalTrial (SINDAS) (NCT02893332).
Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients : a multicenter, single arm, phase II clinical trial
CANOPY-N: A Phase II Study of Canakinumab (CAN) or Pembrolizumab (PEM) as Monotherapy or in Combination as Neoadjuvant Therapy in Patients (Pts) with Surgically Resected (Stage IB-IIIA) Non-Small Cell Lung Cancer (NSCLC)
Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated interim results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Is first line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2) safe? An interim analysis of the multicenter, single-arm SAKK phase II trial 19/17
A phase I clinical study to investigate the safety, tolerability and pharmacokinetics of PD-1 antibody Camrelizumab (SHR-1210) in patients with solid tumor: the results of Non-small cell lung cancer cohort.
Brigatinib (BRG) vs Crizotinib (CRZ) in the Phase 3 ALTA-1L Trial: Updated Results
Patient-reported Outcomes (PROs) From Patients with ROS1-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study
SGNLVA-005: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Lung Malignancies
AcceleRET Lung: A Phase 3 Study of Pralsetinib for First-Line Treatment of RET Fusion+ Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase II trial of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) harboring MET alterations: VISION study
Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small-cell lung cancer
Pembrolizumab for advanced mesothelioma: results from the phase 2 KEYNOTE-158 study
Characterizing safety of dual immunotherapy, nivolumab (NIVO) + ipilimumab (IPI): understanding and managing select treatment-related adverse events (TRAEs) in CheckMate (CM) 227 Part 1
Characterization of responders to nivolumab (NIVO) + ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC) in CheckMate 227 Part 1